M42 Files IPO Prospectus: Pioneering the Future of Integrated, AI-Driven Healthcare

2022Year10Month6Day,G42is a leading artificial intelligence and cloud computing technology company headquartered in the UAE and Mubadala Investment Company, an Abu Dhabi sovereign investment institution (Mubadala) announced that they will merge their respective healthcare businesses into a leading integrated healthcare company in the industry.

This new physical company will integrateG42 HealthcareAdvanced medical and data-driven technologies, withMubadala HealthWorld-class patient care services, providing patient-centered personalized care plans, striving to transform the global healthcare landscape.

Before the merger, the two enterprises served hundreds of thousands of patients each year. After the merger, the new company will continue to leverage the respective strengths of both enterprises, including cutting-edge medical equipment and digital platforms, to enhance patient services throughout the entire care process.

At the forefront of medical research and innovation, the new company is committed to becoming a vertically integrated healthcare giant, providing groundbreaking solutions for unmet clinical needs.Hasan Jasem Al NowaisHas been appointed as the chief executive officer of the new company and will continue to lead.Mubadala Health。

Mubadala HealthChairman andMubadalaDeputy Chief Executive OfficerWaleed Al Mokarrab Al MuhairiRepresentation:“The future of the healthcare sector relies on the rapid advancements in technology. For over a decade,MubadalaProviding the highest standard of patient care across multiple specialties for residents in the UAE. Now, we aim to elevate patient care to a new level, entering a new era of precision and personalized treatment.

Mubadala HealthCEO of Jianxin CompanyHasan Jasem Al NowaisRepresentation:“The new company represents an integrated healthcare ecosystem that combines research, technology, artificial intelligence, and genomics with world-class care to optimize clinical outcomes. We are committed to ensuring that outstanding doctors and care teams have access to cutting-edge medical technology, thereby providing high-quality care to patients.”

While continuing to expand its business in the UAE, the new company will also consider opportunities for international expansion and new partnerships. The new company will also focus on ecosystem collaborations, including partnerships with research, pharmaceutical, and medical technology companies, leveraging the UAE's advanced and future-oriented regulatory framework to bring world-class care to local communities.

The medical assets owned by the two institutions include:Imperial College London Diabetes Centre(Imperial College London Diabetes Centre);HealthPlus；National Reference Laboratory；HealthPoint；Danat Al Emarat(Denet Omarad);Moorfields Eye Hospital Abu Dhabi(Murphy Eye Hospital Dubai Branch);Biogenix Labs； the UAE’s Omics Center of Excellence； Insights Research Organization & Solutions (IROS), this is the first contract research organization in the UAE dedicated to healthcare research.